Analysts Set Omnicell, Inc. (NASDAQ:OMCL) Price Target at $42.20

Omnicell, Inc. (NASDAQ:OMCL) has earned an average rating of “Hold” from the six research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $42.20.

A number of brokerages have issued reports on OMCL. Benchmark reissued a “buy” rating and set a $38.00 target price on shares of Omnicell in a report on Tuesday, April 30th. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Monday.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Gotham Asset Management LLC grew its position in Omnicell by 4.7% during the third quarter. Gotham Asset Management LLC now owns 8,120 shares of the company’s stock worth $366,000 after buying an additional 368 shares in the last quarter. Texas Permanent School Fund Corp grew its holdings in shares of Omnicell by 1.2% during the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock worth $1,158,000 after purchasing an additional 479 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Omnicell by 7.4% in the first quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock worth $265,000 after purchasing an additional 626 shares during the last quarter. Benjamin Edwards Inc. raised its stake in Omnicell by 36.4% in the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after purchasing an additional 868 shares in the last quarter. Finally, Strs Ohio lifted its position in Omnicell by 28.2% during the fourth quarter. Strs Ohio now owns 5,000 shares of the company’s stock valued at $188,000 after purchasing an additional 1,100 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

Shares of OMCL opened at $26.77 on Friday. Omnicell has a 1 year low of $25.12 and a 1 year high of $75.07. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.38 and a quick ratio of 2.13. The stock’s fifty day moving average price is $29.25 and its two-hundred day moving average price is $29.84. The firm has a market cap of $1.23 billion, a PE ratio of -58.20, a PEG ratio of 93.23 and a beta of 0.80.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.17. The business had revenue of $246.15 million for the quarter, compared to the consensus estimate of $235.70 million. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. On average, equities research analysts forecast that Omnicell will post 0.2 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.